Prevention and treatment of pandemic influenza in cancer patients

Annals of Oncology

Volumn 21, Issue 12, 2010, Pages 2301-2303

  Francisci, D ^a   Labianca, R ^b   Roila, F ^c  

^a SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^b OSPEDALI RIUNITI   (Italy)

^c S MARIA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; INFLUENZA VACCINE; OSELTAMIVIR; PNEUMOCOCCUS VACCINE; PREDNISONE; RIBAVIRIN; STREPTOCOCCUS VACCINE; ZANAMIVIR;

ADULT RESPIRATORY DISTRESS SYNDROME; ANTIBIOTIC RESISTANCE; ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL THERAPY; ARTIFICIAL VENTILATION; CANCER INCIDENCE; CANCER PATIENT; CRITICALLY ILL PATIENT; DRUG EFFICACY; DRUG INDICATION; DRUG TREATMENT FAILURE; EDITORIAL; FATALITY; HIGH RISK PATIENT; INFECTION PREVENTION; INFLUENZA A (H1N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; LYMPHOMA; MIXED INFECTION; MYELOMA; PANDEMIC INFLUENZA; PNEUMONIA; PREVALENCE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; SEASONAL VARIATION; STREPTOCOCCUS PNEUMONIA; VIRUS TRANSMISSION;

ADULT; CHILD; DISEASE OUTBREAKS; HUMANS; INFECTION CONTROL; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; NEOPLASMS; PANDEMICS; PREVALENCE; UNITED STATES; YOUNG ADULT;

EID: 78649475850     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq351     Document Type: Editorial

References (29)

1. Garten RJ, Davis CT, Russell CA, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009; 325: 197-201.
2. Miller E, Hoschler K, Hardelid P, et al. Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet 2010; 375: 1100-1108.
3. Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 2010; 362: 1708-1719.
4. The ANZIC Influenza Investigators. Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N Engl J Med 2009; 361: 1925-1934.
5. Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis 2009; 9: 493-504.
6. Yousuf HM, Englund J, Couch R, et al. Influenza among hospitalized adults with leukaemia. Clin Infect Dis 1997; 24: 1095-1099.
7. Chemaly RF, Ghosh S, Bodey GP, et al. Respiratory viral infections in adults with hematologic malignances and human stem cell transplantation recipients: a retrospective study at a major cancer center. Medicine (Baltimore) 2006; 85: 278-287.
8. Schepetiuk S, Papanaoum K, Quiao M. Spread of influenza A virus infection in hospitalised patients with cancer. Aust N Z J Med 1998; 28: 475-476.
9. Cooksley CD, Avritscher EB, Bekele BN, et al. Epidemiology and outcomes of serious influenza-related infections in the cancer population. Cancer 2005; 104: 618-628.
10. Wingard JR. Influenza: preparedness for an inevitable "mergency"for oncology and BMT units. J Natl Compr Canc Netw 2008; 6: 215-222.
11. Kharfan-Dabaja MA, Velez A, Richards K, et al. Influenza A/pandemic 2009/H1N1 in the setting of allogenic hematopoietic cell transplantation: a potentially catastrophic problem in a vulnerable population. Int J Hematol 2009; 91: 124-127.
12. Redelman-Sidi G, Sepkowitz KA, Huang KA, et al. 2009 H1N1 influenza infection in cancer patients and hematopoietic stem cell transplant recipients. J Infect 2010; 60: 257-263.
13. Hajjar LA, Mauad T, Gomes Galas FRB, et al. Severe novel influenza A (H1N1) infection in cancer patients. Ann Oncol 2010; 21: 2333-2341.
14. Nordøy T, Aaberge IS, Husebekk A, et al. Cancer patients undergoing chemotherapy show adequate serological response to vaccination against influenza virus and Streptococcus pneumoniae. Med Oncol 2002; 19: 71-78.
15. Pollyea DA, Brown JM, Horning SJ. Utility of influenza vaccination for oncology patients. J Clin Oncol 2010; 28: 2481-2490.
16. Mazza JJ, Yale SH, Arrowood JR, et al. Efficacy of the influenza vaccine in patients with malignant lymphoma. Clin Med Res 2005; 3: 214-220.
17. Shih YC, Pan IW. Influenza vaccination among individuals with cancer and their family members. Am J Prev Med 2010; 38: 61-69.
18. Weinstock DM, Eagan J, Malak SA, et al. Control of influenza A on a bone marrow transplant unit. Infect Control Hosp Epidemiol 2000; 21: 730-732.
19. Tilburt JC, Mueller PS, Ottenberg AL, et al. Facing the challenges of influenza in healthcare settings: the ethical rationale for mandatory seasonal influenza vaccination and its implications for future pandemics. Vaccine 2008; 26 (Suppl 4): 27-30.
20. Centers for Disease Control and Prevention (CDC). Bacterial coinfections in lung tissue specimens from fatal cases of 2009 pandemic influenza A (H1N1) in United States, May-August 2009. MMWR Morb Mortal Wkly Rep. 2009; 58: 1071-1074.
21. Hartkamp A, Mulder AH, Rijkers GT, et al. Antibody responses to pneumococcal and haemophilus vaccinations in patients with B-cell chronic lymphocytic leukemia. Vaccine 2001; 19: 1671-1677.
22. Molrine DC. Recommendations for immunizations in stem cell transplantation. Pediatr Transplant 2003; 7 (Suppl.3): 76-85.
23. Casper C, Englund J, Boeckh M. How I treat influenza in patients with hematologic malignances. Blood 2010; 115: 1331-1342.
24. Aoki FY, Macleod MD, Paggiaro P, et al. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother 2003; 51: 123-129.
25. Dominguez-Cherit G, Lapinsky SE, Macias AE, et al. Critically ill patients with 2009 influenza A(H1N1) in Mexico. JAMA 2009; 302: 1880-1887.
26. Englund JA, Champlin RE, Wyde PR, et al. Common emergence of amantadineand rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults. Clin Infect Dis 1998; 26: 1418-1424.
27. Seiter K, Nadelman RB, Liu D, et al. Novel Influenza A(H1N1) in patients with hematologic malignances. J Clin Oncol 2010; 28: e27-e29.
28. Nguyen JT, Hoopes JD, Le MH, et al. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS One 2010; 5: e9332.
29. Peek GJ, Mugford M, Tiruvoipati R, et al. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet 2009; 374: 1351-1363.